EP2389361A2 — Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
Assigned to Molecular Insight Pharmaceuticals Inc · Expires 2011-11-30 · 14y expired
What this patent protects
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific …
USPTO Abstract
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.